Effect of Electroacupuncture on Benign Prostatic Hyperplasia

Not Applicable

Recruiting

• Conditions: Benign Prostatic Hyperplasia
• Interventions: Device: Electroacupuncture; Device: Sham electroacupuncture

• Registration Number: NCT05585450
• Lead Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Brief Summary

The study aims to assess the efficacy and safety of electroacupuncture among men with benign prostatic hyperplasia (BPH), compared with sham electroacupuncture.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-10-13
• Study First Submitted QC: 2022-10-15
• Study First Posted: 2022-10-18
• Study Start: 2023-03-09
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-17
• Last Update Posted: 2024-07-18
• Primary Completion: 2025-09-30
• Study Completion: 2025-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Male
• Target Recruitment: 306

Inclusion Criteria

1. Diagnosis of BPH in accordance with the European Association of Urology (EAU) guideline;
2. Male participants aged between 40 and 80 years;
3. Lower urinary tract symptoms (LUTS) for at least three months;
4. IPSS total score ≥8;
5. Prostate volume ≥20 mL;
6. Urinary peak flow rate (Qmax) ≤15 mL/s;
7. Voluntary participation in the trial and signed written informed content.

Exclusion Criteria

1. Post-void residual urine volume (PVR) ≥150 mL;
2. Acute urinary retention or catheterization for outflow obstruction within the 3 months (Except for post-surgical disposable catheterization);
3. Prostate cancer or prostate-specific antigen (PSA) level ≥4.0 ng/mL;
4. Neurogenic lower urinary tract dysfunction; prostatitis; uncontrolled symptomatic urinary tract infections; urethral strictures; bladder diverticula; bladder stones; bladder cancer; history of genitourinary system surgery (prostate, bladder, urethra, etc.);
5. Previous acupuncture treatment for BPH in the preceding one month, or α-blockers, 5α-reductase inhibitor, muscarinic receptor antagonists, or any other specific medication usage in the previous two weeks unless a stable 5α-reductase inhibitor usage of over three months;
6. Severe lung, heart, liver, kidney, metabolic, or mental illness, coagulation dysfunction, or with obvious cognitive dysfunction;
7. Installed cardiac pacemaker, allergy to metal, severe fear of acupuncture or unbearable to the stimulation of EA.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Electroacupuncture (EA) group	Electroacupuncture	Participants in the EA group will receive treatment at bilateral Bladder Meridian (BL) 32 \[Ciliao\], BL33 \[Zhongliao\], BL35 \[Huiyang\], and Spleen Meridian (SP) 6 \[Sanyinjiao\]. BL32, in the second posterior sacral foramen; BL33, in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; SP6, posterior to the medial border of the tibia, 3 cun (≈60mm) superior to the prominence of the medial malleolus. The treatment will last 30 minutes for each session, 3 sessions per week (ideally every other day) for a succession of 8 weeks.
Sham Electroacupuncture (SA) group	Sham electroacupuncture	Participants in the SA group will receive treatment at bilateral sham BL32, BL33, BL35, and SP6. Sham BL32, in the area of 2 cun (≈40mm) horizontally outside BL32; Sham BL33, in the area of 2 cun (≈40mm) horizontally outside BL33; Sham BL35, 2 cun (≈40mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The treatment will last 30 minutes for each session, 3 sessions per week (ideally every other day) for a succession of 8 weeks.

Primary Outcome Measures

Name	Time	Method
The proportion of participants with at least 30% reduction in the total score of International Prostate Symptom Score (IPSS) from baseline	week 20	The IPSS is a valid, reliable, and sensitive measure tool frequently used to evaluate the severity of lower urinary tract symptoms, including incomplete bladder emptying, frequency of urination, intermittency, urgency, weak urine stream, straining, and nocturia. The score of IPSS ranges from 0 to 35, with scores of 0 to 7 indicating mild symptoms; 8 to 19 indicating moderate symptoms; and 20 to 35 indicating severe symptoms.

Secondary Outcome Measures

Name	Time	Method
The change from baseline in the total score of IPSS	weeks 4, 8, 12, 20, 32	The IPSS is a valid, reliable, and sensitive measure tool frequently used to evaluate the severity of lower urinary tract symptoms, including incomplete bladder emptying, frequency of urination, intermittency, urgency, weak urine stream, straining, and nocturia. The score of IPSS ranges from 0 to 35, with scores of 0 to 7 indicating mild symptoms; 8 to 19 indicating moderate symptoms; and 20 to 35 indicating severe symptoms.
The proportion of participants with at least 30% reduction in the total score of IPSS from baseline	weeks 4, 12, 32	The IPSS is a valid, reliable, and sensitive measure tool frequently used to evaluate the severity of lower urinary tract symptoms, including incomplete bladder emptying, frequency of urination, intermittency, urgency, weak urine stream, straining, and nocturia. The score of IPSS ranges from 0 to 35, with scores of 0 to 7 indicating mild symptoms; 8 to 19 indicating moderate symptoms; and 20 to 35 indicating severe symptoms.
The proportion of participants with at least 50% reduction in the total score of IPSS from baseline	weeks 4, 8, 12, 20, 32	The IPSS is a valid, reliable, and sensitive measure tool frequently used to evaluate the severity of lower urinary tract symptoms, including incomplete bladder emptying, frequency of urination, intermittency, urgency, weak urine stream, straining, and nocturia. The score of IPSS ranges from 0 to 35, with scores of 0 to 7 indicating mild symptoms; 8 to 19 indicating moderate symptoms; and 20 to 35 indicating severe symptoms.
The change from baseline in the voiding and storage subscale scores of IPSS	weeks 4, 8, 12, 20, 32	The IPSS is a valid, reliable, and sensitive measure tool frequently used to evaluate the severity of lower urinary tract symptoms, including incomplete bladder emptying, frequency of urination, intermittency, urgency, weak urine stream, straining, and nocturia. The score of IPSS ranges from 0 to 35, with scores of 0 to 7 indicating mild symptoms; 8 to 19 indicating moderate symptoms; and 20 to 35 indicating severe symptoms.
The change from baseline in the quality of life (QOL) item of IPSS	weeks 4, 8, 12, 20, 32	Participants will be asked the question: If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that? The response categorized into 7 degrees scoring 0 to 6, respectively: 0 (delighted), 1 (pleased), 2 (mostly satisfied), 3 (mixed about equally satisfied and dissatisfied), 5 (mostly dissatisfied), 5 (unhappy), and 6 (terrible).
The change from baseline in the BPH Impact Index (BPH-II)	weeks 4, 8, 12, 20, 32	The BPH-II measures the interference of LUTS in patients' mental health and activity. The total score of BPH-II ranges from 0 to 13, with higher scores indicating poorer quality of life.
The change from baseline in the International Index of Erectile Function 5 (IIEF-5)	weeks 8, 20, 32	The IIEF-5 is a valid and reliable instrument for detecting treatment effects in patients with erection dysfunction, ranging from 1 to 25, with lower scores indicating more severe dysfunction.
The change from baseline in the hours of undisturbed sleep (HUS)	weeks 4, 8, 12, 20, 32	HUS is defined as the duration from falling asleep till awake in the morning, or till the first nocturia if any.
The change from baseline in the number of nocturia	weeks 4, 8, 12, 20, 32	Participants will be asked: During the last month, how many times did you most typically get up to urinate from the time you went to bed at night until the time you got up in the morning?
The change from baseline in the Hospital Anxiety and Depression Scale (HADS)	weeks 8, 20, 32	The HADS score ranges from 0 to 42, with higher scores indicating greater anxiety and depression.
The change from baseline in the volume of prostate	week 8	The prostate volume will be measured by transabdominal ultrasound.
The change from baseline in the post-void residual urine volume	week 8	The post-void residual urine volume will be measured by transabdominal ultrasound.
The change from baseline in the urinary peak and average flow rate	week 8	The urinary peak and average flow rate will be measured by uroflowmetry.
The proportion of responders per the Patient Global Index of Improvement (PGI-I)	weeks 8, 20, 32	The PGI-I evaluates the overall treatment effect perceived by patients themselves. The change can be rated in 7 levels, including "very much better", "much better", "a little better", "no change", "a little worse", "much worse" or "very much worse".

Trial Locations

Locations (1)

Guang'anmen Hospital, China Academy of Chinese Medical Sciences; 🇨🇳 Beijing, Beijing, China